profile

Oncology Hero

Itovebi Cuts Breast Cancer Mortality, Candel’s Oncolytic Virus Boosts Prostate Outcomes

Published 5 months ago • 1 min read

​

​

Roche’s Itovebi Cuts Risk of Death by 33% in HER2-Positive Breast Cancer

Context: HER2-positive breast cancer remains an aggressive subtype despite advances in targeted therapies.

What's New? In updated data presented at ASCO, Roche’s anti-HER2 therapy Itovebi (trastuzumab duocarmazine) reduced the risk of death by 33% in pretreated HER2-positive breast cancer, significantly improving overall survival compared to standard therapies.

Why it Matters? This reinforces Itovebi’s growing role in HER2+ treatment and supports further positioning as a key ADC in Roche’s expanding breast cancer portfolio.

​Read More​

Elahere Demonstrates Superiority Over Chemotherapy in Ovarian Cancer

Context: FRα-targeted therapy Elahere has reshaped treatment options in platinum-resistant ovarian cancer.

What's New? New data confirm Elahere significantly improves overall and progression-free survival compared with standard chemotherapy in FRα-high ovarian cancer, reinforcing its front-runner status among ADCs in gynecologic oncology.

Why it Matters? These results strengthen Elahere’s clinical value and may prompt broader use earlier in the treatment paradigm, potentially setting a new standard of care.

​Read More​

Candel’s Oncolytic Virus Shows Durable Survival in Prostate Cancer

Context: Immunotherapy success has been limited in prostate cancer due to low tumor immunogenicity.

What's New? Candel Therapeutics released final data showing its oncolytic viral immunotherapy CAN-2409 in combination with valacyclovir led to a significant survival advantage and T-cell activation in non-metastatic prostate cancer patients, improving outcomes after radiation therapy.

Why it Matters? These results support CAN-2409’s potential as a novel platform to enhance immune response in historically immunotherapy-resistant tumors like prostate cancer.

​Read More​

GLP-1s and Bariatric Surgery Offer Comparable Reductions in Obesity-Linked Cancer Risk

Context: Obesity is a major modifiable risk factor for multiple cancer types, but comparative cancer-preventive data across interventions remain limited.

What's New? A new study shows that patients taking GLP-1 receptor agonists had similar reductions in obesity-related cancer risk as those undergoing bariatric surgery, suggesting metabolic therapy may offer meaningful cancer prevention benefits.

Why it Matters? These findings highlight the broader oncologic value of GLP-1 drugs and may shift the conversation toward medical management of cancer risk in metabolic disease populations.

​Read More​

​

Oncology Hero

Sharing the latest updates in oncology

Read more from Oncology Hero

In partnership with Oncology Updates — Aug 26 to Sep 2025 September delivered practice-relevant oncology updates worldwide — guideline shifts, pivotal trial readouts, new approvals, and high-impact AI tools. Below is a concise, clinician-first roundup. 🎗️ 🩺Lung cancer ESMO issues NSCLC guideline for early & locally advanced disease New recommendations standardize biomarker-driven multimodality care in stage I–III NSCLC, including integration of IO/targeted therapy in pathways. Read more...

24 days ago • 3 min read

Oncology Updates — August 2025 August 2025 delivered practice-relevant oncology updates worldwide — fresh guideline shifts, pivotal trial readouts, new approvals, diagnostics/devices, and high-impact AI tools. Below is a concise, clinician-first roundup, capped with a focused deep dive on the updated ASCO NSCLC guidelines. 🎗️ 💼 Earn for training the next generation of AI tools Medical Expert Hourly contract · Remote · $130–$180 per hour Apply here Physicians, Pathologists (Health Care and...

about 2 months ago • 2 min read

Regeneron Acquires 23andMe Research Division for $256M in Bankruptcy Auction Context: As 23andMe navigates Chapter 11 proceedings, key assets tied to its vast genomic database and pharma partnerships have drawn industry attention. What's New? Regeneron has secured a $256 million deal to acquire 23andMe’s therapeutics subsidiary, aiming to leverage the platform’s extensive genotypic and phenotypic data to fuel its precision medicine pipeline. Why it Matters? This acquisition gives Regeneron a...

5 months ago • 1 min read